Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 0.58 |
| ▸ | ZAP70 | P43403 | 10/20 | 0.58 |
| ▸ | SRC | P12931 | 8/20 | 0.58 |
| ▸ | CDK2 | P24941 | 4/20 | 0.58 |
| ▸ | FLT3 | P36888 | 8/20 | 0.48 |
| ▸ | JAK2 | O60674 | 7/20 | 0.48 |
| ▸ | LYN | P07948 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL144714 | 0.81 | SYK (0.64) | SYKZAP70SRCCDK2FLT3 | |
| SCHEMBL6026875 | 0.80 | SYK (0.66) | SYKZAP70SRCCDK2FLT3 | |
| SCHEMBL14216119 | 0.74 | SYK (0.77) | SYKZAP70SRCCDK2 | |
| SCHEMBL5034190 | 0.73 | SYK (0.76) | SYKZAP70SRCCDK2FLT3 | |
| SCHEMBL7471347 | 0.72 | SRC (0.64) | SYKZAP70SRCCDK2JAK2 | |
| SCHEMBL14216039 | 0.72 | SYK (0.74) | SYKZAP70SRCCDK2FLT3 | |
| SCHEMBL13924509 | 0.72 | SYK (1.00) | SYKZAP70SRCCDK2 | |
| SCHEMBL14216294 | 0.72 | SYK (0.77) | SYKZAP70SRCCDK2 | |
| SCHEMBL7464938 | 0.71 | KDR (0.64) | SYKZAP70SRCCDK2FLT3 | |
| SCHEMBL25329124 | 0.71 | SYK (0.51) | SYKZAP70SRCCDK2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1610793-A2 | THIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2006-01-04 | — | — | EP | disclosed |
| US-20040235834-A1 | Thiazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2004-11-25 | — | — | US | disclosed |
| WO-2004087698-A2 | THIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235834-A1 | Thiazoles useful as inhibitors of protein kinases | PRKACA, MAP3K20, MAP3K6 | SYK 510/4885ZAP70 407/4885SRC 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.